CN101091718A - Injection for preventing kidney disease caused by contrast agent - Google Patents
Injection for preventing kidney disease caused by contrast agent Download PDFInfo
- Publication number
- CN101091718A CN101091718A CN 200610028143 CN200610028143A CN101091718A CN 101091718 A CN101091718 A CN 101091718A CN 200610028143 CN200610028143 CN 200610028143 CN 200610028143 A CN200610028143 A CN 200610028143A CN 101091718 A CN101091718 A CN 101091718A
- Authority
- CN
- China
- Prior art keywords
- injection
- contrast agent
- kidney disease
- disease caused
- radiographic contrast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention relates to an injection capable of effectively preventing nephropathy due to contrast medium. Said injection is made up by using (by wt %) 1-2.5% of sodium hydrogen carbonate and 0.01-0.05% of disodium egtazate through a certain preparation process. Said invention also provides the mechanism of action of said injection.
Description
Technical field
The present invention relates to a kind of injection, a kind of injection that prevents radiographic contrast nephropathy of more specifically saying so.
Background information
China is hypertension, diabetes, high blood ester, the multiple country of metabolic arthritis, and is in the rising stage of this class disease incident, and the present aging population absolute number of China is more in addition, and the incidence rate of ischemic nephropathy is higher; China still is the multiple country of ascending infection kidney disease in addition, and west area renal glomerular disease incidence rate is higher, in this class crowd as carry out phlebography when checking, radiographic contrast nephropathy takes place easily.Radiographic contrast nephropathy is a kind of foreseeable kidney disease, and preventive effect is undesirable always simultaneously.
Summary of the invention
At the problems referred to above, the present invention intends providing a kind of injection that prevents radiographic contrast nephropathy.
For achieving the above object, the present invention has adopted following technical scheme: a kind of injection that prevents radiographic contrast nephropathy, it contains weight content is the 1-2.5% sodium bicarbonate.
The injection of above-mentioned prevention radiographic contrast nephropathy, it also contains the disodium edetate that weight content is 0.01-0.05%.
The occurring principle of radiographic contrast nephropathy is, after contrast agent entered the kidney medullary substance, the renal medulla pH value descended, and will promote the Haber-Weiss that is drawn by superoxides to react, Haber Weiss reaction be many oxidations disease mediated in free radical generate mechanism, reaction equation is Fe
3++ O
2 -→ Fe
2++ O
2Fe
2++ H
2O
2→ Fe
3++ OH+OH
-, the producing method of this oxyradical can be by trace iron catalysis, and reaction is the most active in (PKa=4.9) under acid PH environment
(3-6)When pH value under neutrallty condition, non-compound ferric ion can precipitate with the form of insolubility hydrated ferric oxide., sodium bicarbonate can reduce free radical and generate from the Haber-Weiss reaction, thereby stop oxidative damage by improving the renal medulla pH value.Sodium bicarbonate still can be removed peroxide and hardening agent peroxynitrite salt and other the oxidation activity products that is generated by nitric oxide that produces owing to the renal medulla ischemia simultaneously, thereby further stops the kidney injury due to the oxidation product.
The specific embodiment
The sodium bicarbonate molecular formula is a NaHCO molecular weight 84.01, as to adopt injection of the present invention be the sterilizing injecting solution of 1.25% sodium bicarbonate, pharmacopeia regulation safe level error is 1.25% ± 5%, be 1.1875-1.3125%, the loading amount error is 500ml ± 5%, be 475-525ml, 1000ml ± 5%, i.e. 9500-1050ml.
As preferably adding disodium edetate (Calcium Disodium Versenate) in addition
Structural formula is as follows:
Molecular formula C
10H
12N
2-Na
2O
8, 6H
2O molecular weight 442.3 pharmacopeia regulation allowances are 0.01% ~ 0.05% to be for 10mg ~ 50mg among every 100ml.The liquid colour-changeable that plays anti-oxidation effect and cause and play combination with heavy metal.
Dosage form
Two kinds of bottled errors of 1% or 1.25% or 1.5% or 2.0% or 2.5% sodium bicarbonate injection 500ml and 1000ml are between 475-525ml and 950-1050ml, and concentration error is a 1.1875-1.3125% sodium bicarbonate scope.
Also can contain disodium edetate simultaneously is 0.01% or 0.02% or 0.03% or 0.04% or 0.05%.
The method of preparing injection of the present invention is identical with traditional injection.
The clinical observation on the therapeutic effect data
One, inclusion criteria
1. age 〉=18 year old, serum creatinine level is stabilized in 〉=97.2umol/L (1.1mg/dL)
2. use non-ionic contrast medium 76% diatrizoate meglumine inj [Compound Meglumine DiatrizoateInjection contains sodium amidotrizoate 32mg, cardiografin 268mg, 796mosm/kg, content of iodine 370mg/ml, Na ion concentration 136mmol/L] radiography person.[being mainly used in cardiac catheter, cerebrovascular, the scanning of electronic computer x-ray tomography (CT) and magnetic resonance (MRI)] used when selecting shadow.
Two, forbid inclusion criteria
Serum creatinine level 〉=707umol/L (1.1mgl/dL), pulmonary edema, multiple myeloma were used contrast agent in 2 days, and contrast agent allergy was used mannitol in 2 days, N-acetylcystein, dopamine etc.
Three, diagnostic criteria
Radiographic contrast nephropathy uses that serum creatinine raises 〉=25% in the contrast agent 2 days; Serum creatinine rising 〉=50% in 2 days behind the severe radiographic contrast nephropathy use contrast agent.
Four, using method
Before radiography, with 1.25% sodium bicarbonate solution intravenous drip 200-250ml (or 3-3.5ml/kg), contrast agent use posterior vein persistent instillation per hour 60-80ml (or 1-1.2ml/kg) continues 6 hours, and urine PH value of monitoring in every 4-6 hour and serum creatinine amount to everyone 12--16 time.
Five, clinical data
250 examples are organized in the treatment of I group, male 150 examples, women 100 examples, age 26-85 year, median 58.2 years old.II organizes matched group, male 155 examples, women 95 examples, age 26-86 year, median 57.4 years old.Serum creatinine level before the sick kind of two groups of patients, blood pressure, blood glucose, blood ester, body weight, the treatment is used contrast agent dosage size zero difference.
Six, result
Treatment group generation radiographic contrast nephropathy incidence rate is 1.6% (4/250), severe radiographic contrast nephropathy person 1 example takes place, account for 0.4%; Matched group generation radiographic contrast nephropathy person incidence rate is 12% (30/250), and severe radiographic contrast nephropathy person 6 examples take place, and accounts for 2.4%, and promptly per 10.4 examples can be prevented 1 routine radiographic contrast nephropathy.Difference has significance.
Claims (2)
1, a kind of injection that prevents radiographic contrast nephropathy is characterized in that it contains weight content is the 1-2.5% sodium bicarbonate.
2, the injection of prevention radiographic contrast nephropathy according to claim 1 is characterized in that also containing the disodium edetate that weight content is 0.01-0.05%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610028143 CN101091718A (en) | 2006-06-22 | 2006-06-22 | Injection for preventing kidney disease caused by contrast agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610028143 CN101091718A (en) | 2006-06-22 | 2006-06-22 | Injection for preventing kidney disease caused by contrast agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101091718A true CN101091718A (en) | 2007-12-26 |
Family
ID=38990276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610028143 Pending CN101091718A (en) | 2006-06-22 | 2006-06-22 | Injection for preventing kidney disease caused by contrast agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101091718A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552267A (en) * | 2012-02-17 | 2012-07-11 | 上海市中医医院 | Application of tetramethylpyrazine to preparation of medicine for treating contrast-induced nephropathy |
| CN105456840A (en) * | 2015-12-11 | 2016-04-06 | 闫景伟 | Traditional Chinese medicine for treating radiographic contrast nephropathy for department of image and preparation method of traditional Chinese medicine |
-
2006
- 2006-06-22 CN CN 200610028143 patent/CN101091718A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552267A (en) * | 2012-02-17 | 2012-07-11 | 上海市中医医院 | Application of tetramethylpyrazine to preparation of medicine for treating contrast-induced nephropathy |
| CN105456840A (en) * | 2015-12-11 | 2016-04-06 | 闫景伟 | Traditional Chinese medicine for treating radiographic contrast nephropathy for department of image and preparation method of traditional Chinese medicine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mancini et al. | Hemodynamic and electrocardiographic effects in man of a new nonionic contrast agent (iohexol): advantages over standard ionic agents | |
| Gutman et al. | A study, by simultaneous clearance techniques, of salicylate excretion in man. Effect of alkalinization of the urine by bicarbonate administration; effect of probenecid | |
| EP3284463B1 (en) | Nitroxyl donors with improved therapeutic index | |
| KR20080082674A (en) | Methods and compositions for administration of iron | |
| Aikawa et al. | Magnesium metabolism in human beings: studies with Mg28 | |
| CN102247317A (en) | Vitamin c injection and preparation method thereof | |
| Durbin et al. | Specific Sequestering Agents for the Actinides: 4. Removal of 238Pu (IV) from Mice by Sulfonated Tetrameric Catechoyl Amides | |
| CN114404618A (en) | Aqueous radiopharmaceutical solutions and their use | |
| US5393777A (en) | Deferration using anguibactin siderophore | |
| Briguori et al. | Renal insufficiency following contrast media administration trial III: Urine flow rate‐guided versus left‐ventricular end‐diastolic pressure‐guided hydration in high‐risk patients for contrast‐induced acute kidney injury. Rationale and design | |
| US5169858A (en) | Anti-tumor compositions containing the reactive product of benzaldehyde or salicylaldehyde with penicillamine and method of use thereof | |
| CN101091718A (en) | Injection for preventing kidney disease caused by contrast agent | |
| Gordon et al. | Ethylene glycol poisoning: A case report | |
| CN109316474B (en) | Application of deferoxamine in preparation of drugs for preventing and/or treating tumors | |
| Monclair et al. | Characteristics of transcellular NaCl reabsorption in the kidney | |
| Violante et al. | Ventricular fibrillation from diatrizoate with and without chelating agents | |
| US3062719A (en) | Trisodium calcium diethylenetriaminepentaacetic acid, compositions containing the same, and the use thereof | |
| Steinberg et al. | Conray: A new cardiovascular and urographie contrast medium | |
| Lauret et al. | Vegetating iodides after an intravenous pyelogram | |
| BJÖRK et al. | Clinical experience with a new type of contrast medium in carotid arteriography | |
| EP0572963B1 (en) | Sclerosing solution | |
| BJÖRK et al. | Clinical experience with a new type of contrast medium in angiocardiography and thoracic aortography | |
| RU2162714C1 (en) | Radiopharmaceutical composition | |
| Rubbo et al. | Chemotherapy of Tuberculosis: II. Some Observations on the Pharmacology of Verazide | |
| US20030045586A1 (en) | Use of amines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20071226 |